User login
SAN DIEGO – Among individuals with a history of injection drug use, more than one-third reported never or sometimes carrying naloxone, while just one in four reported carrying with it them at all times.
Those are key findings from a survey that set out to examine gaps in the naloxone cascade in a sample of people who inject drugs.
“In order to save a life, you have to have the naloxone with you at all times,” lead study author Karin E. Tobin, PhD, said in an interview at the annual meeting of the College on Problems of Drug Dependence.
While emerging research demonstrates the positive impact of opioid overdose education and community naloxone distribution programs to reduce opioid-related overdose deaths, opiate overdose continues to be a major cause of mortality, said Dr. Tobin, who is affiliated with the department of health behavior and society at Johns Hopkins University, Baltimore. “We’ve made a lot of progress in convincing people that naloxone is not addictive, and that it’s not going to cause any harm,” she said. “Now, drug users aren’t afraid to ask for it. Still, we wondered: If everyone knows about naloxone and no one is embarrassed to talk about it, why are people still dying [from opioid overdoses] in Baltimore?”
She and her associates conducted a cross-sectional survey of 353 individuals aged 18 and older in Baltimore who self-reported a lifetime history of injection drug use. The data came from a baseline survey that was conducted as part of a randomized, controlled trial testing the efficacy of a behavioral intervention focused on the Hepatitis C cascade. Individuals were asked to answer questions related to the five steps of the naloxone cascade: awareness (have you ever heard about naloxone?), access (have you ever received naloxone?), training (have you ever been trained to use naloxone?), use (have you ever used naloxone during an opiate overdose?), and possession (how often do you carry naloxone?)
More than half of the survey respondents (65%) were male; mean age was 47 years. For the previous 6 months, more than half of the sample reported the use of crack (64%), heroin (74%), and other injectable drugs (57%), while 90% reported having ever witnessed an overdose – 59% in the prior year alone. Dr. Tobin and her associates found that 90% of respondents had heard about naloxone, 69% had received it, and 60% had been trained to use it. In addition, 37% reported never carrying naloxone, 38% sometimes carried it, 33% said they had used naloxone at some point, and 25% said they always carried it with them.
On multinomial regression analysis, the researchers found that carrying naloxone often or always was significantly associated with the following variables: female sex (odds ratio, 2.77), having ever witnessed an overdose (OR, 1.84), having injected in the past 12 months (OR, 1.75), and having ever used naloxone during an overdose (OR, 4.33). The latter finding is especially important, “because it means that we just have to let people practice using it,” said Dr. Tobin, who noted that more research is needed to understand reasons why injection drug users do not always carry naloxone. “We need to start changing the social norms about carrying naloxone. You never know when it will be useful.”
The National Institute on Drug Abuse supported the study. Dr. Tobin reported having no financial disclosures.
SAN DIEGO – Among individuals with a history of injection drug use, more than one-third reported never or sometimes carrying naloxone, while just one in four reported carrying with it them at all times.
Those are key findings from a survey that set out to examine gaps in the naloxone cascade in a sample of people who inject drugs.
“In order to save a life, you have to have the naloxone with you at all times,” lead study author Karin E. Tobin, PhD, said in an interview at the annual meeting of the College on Problems of Drug Dependence.
While emerging research demonstrates the positive impact of opioid overdose education and community naloxone distribution programs to reduce opioid-related overdose deaths, opiate overdose continues to be a major cause of mortality, said Dr. Tobin, who is affiliated with the department of health behavior and society at Johns Hopkins University, Baltimore. “We’ve made a lot of progress in convincing people that naloxone is not addictive, and that it’s not going to cause any harm,” she said. “Now, drug users aren’t afraid to ask for it. Still, we wondered: If everyone knows about naloxone and no one is embarrassed to talk about it, why are people still dying [from opioid overdoses] in Baltimore?”
She and her associates conducted a cross-sectional survey of 353 individuals aged 18 and older in Baltimore who self-reported a lifetime history of injection drug use. The data came from a baseline survey that was conducted as part of a randomized, controlled trial testing the efficacy of a behavioral intervention focused on the Hepatitis C cascade. Individuals were asked to answer questions related to the five steps of the naloxone cascade: awareness (have you ever heard about naloxone?), access (have you ever received naloxone?), training (have you ever been trained to use naloxone?), use (have you ever used naloxone during an opiate overdose?), and possession (how often do you carry naloxone?)
More than half of the survey respondents (65%) were male; mean age was 47 years. For the previous 6 months, more than half of the sample reported the use of crack (64%), heroin (74%), and other injectable drugs (57%), while 90% reported having ever witnessed an overdose – 59% in the prior year alone. Dr. Tobin and her associates found that 90% of respondents had heard about naloxone, 69% had received it, and 60% had been trained to use it. In addition, 37% reported never carrying naloxone, 38% sometimes carried it, 33% said they had used naloxone at some point, and 25% said they always carried it with them.
On multinomial regression analysis, the researchers found that carrying naloxone often or always was significantly associated with the following variables: female sex (odds ratio, 2.77), having ever witnessed an overdose (OR, 1.84), having injected in the past 12 months (OR, 1.75), and having ever used naloxone during an overdose (OR, 4.33). The latter finding is especially important, “because it means that we just have to let people practice using it,” said Dr. Tobin, who noted that more research is needed to understand reasons why injection drug users do not always carry naloxone. “We need to start changing the social norms about carrying naloxone. You never know when it will be useful.”
The National Institute on Drug Abuse supported the study. Dr. Tobin reported having no financial disclosures.
SAN DIEGO – Among individuals with a history of injection drug use, more than one-third reported never or sometimes carrying naloxone, while just one in four reported carrying with it them at all times.
Those are key findings from a survey that set out to examine gaps in the naloxone cascade in a sample of people who inject drugs.
“In order to save a life, you have to have the naloxone with you at all times,” lead study author Karin E. Tobin, PhD, said in an interview at the annual meeting of the College on Problems of Drug Dependence.
While emerging research demonstrates the positive impact of opioid overdose education and community naloxone distribution programs to reduce opioid-related overdose deaths, opiate overdose continues to be a major cause of mortality, said Dr. Tobin, who is affiliated with the department of health behavior and society at Johns Hopkins University, Baltimore. “We’ve made a lot of progress in convincing people that naloxone is not addictive, and that it’s not going to cause any harm,” she said. “Now, drug users aren’t afraid to ask for it. Still, we wondered: If everyone knows about naloxone and no one is embarrassed to talk about it, why are people still dying [from opioid overdoses] in Baltimore?”
She and her associates conducted a cross-sectional survey of 353 individuals aged 18 and older in Baltimore who self-reported a lifetime history of injection drug use. The data came from a baseline survey that was conducted as part of a randomized, controlled trial testing the efficacy of a behavioral intervention focused on the Hepatitis C cascade. Individuals were asked to answer questions related to the five steps of the naloxone cascade: awareness (have you ever heard about naloxone?), access (have you ever received naloxone?), training (have you ever been trained to use naloxone?), use (have you ever used naloxone during an opiate overdose?), and possession (how often do you carry naloxone?)
More than half of the survey respondents (65%) were male; mean age was 47 years. For the previous 6 months, more than half of the sample reported the use of crack (64%), heroin (74%), and other injectable drugs (57%), while 90% reported having ever witnessed an overdose – 59% in the prior year alone. Dr. Tobin and her associates found that 90% of respondents had heard about naloxone, 69% had received it, and 60% had been trained to use it. In addition, 37% reported never carrying naloxone, 38% sometimes carried it, 33% said they had used naloxone at some point, and 25% said they always carried it with them.
On multinomial regression analysis, the researchers found that carrying naloxone often or always was significantly associated with the following variables: female sex (odds ratio, 2.77), having ever witnessed an overdose (OR, 1.84), having injected in the past 12 months (OR, 1.75), and having ever used naloxone during an overdose (OR, 4.33). The latter finding is especially important, “because it means that we just have to let people practice using it,” said Dr. Tobin, who noted that more research is needed to understand reasons why injection drug users do not always carry naloxone. “We need to start changing the social norms about carrying naloxone. You never know when it will be useful.”
The National Institute on Drug Abuse supported the study. Dr. Tobin reported having no financial disclosures.
AT CPDD 2018
Key clinical point: Increasing possession of naloxone among people who use opiates is essential.
Major finding:. Carrying naloxone often or always was significantly associated with several variables, including female sex (odds ratio, 2.77) and having ever used naloxone during an overdose (OR, 4.33).
Study details: A cross-sectional survey of 353 individuals aged 18 and older in Baltimore who self-reported a lifetime history of injection drug use.
Disclosures: The National Institute on Drug Abuse supported the study. Dr. Tobin reported having no financial disclosures.